IL89227A - Method of screening of protein inhibitors and activators - Google Patents
Method of screening of protein inhibitors and activatorsInfo
- Publication number
- IL89227A IL89227A IL8922789A IL8922789A IL89227A IL 89227 A IL89227 A IL 89227A IL 8922789 A IL8922789 A IL 8922789A IL 8922789 A IL8922789 A IL 8922789A IL 89227 A IL89227 A IL 89227A
- Authority
- IL
- Israel
- Prior art keywords
- cell
- protein
- response
- substance
- phenotypic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 239000012190 activator Substances 0.000 title claims abstract description 36
- 238000012216 screening Methods 0.000 title description 19
- 229940121649 protein inhibitor Drugs 0.000 title description 4
- 239000012268 protein inhibitor Substances 0.000 title description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 149
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 99
- 239000000126 substance Substances 0.000 claims abstract description 42
- 229920001817 Agar Polymers 0.000 claims abstract description 39
- 239000008272 agar Substances 0.000 claims abstract description 39
- 239000003112 inhibitor Substances 0.000 claims abstract description 37
- 230000008859 change Effects 0.000 claims abstract description 26
- 238000004113 cell culture Methods 0.000 claims abstract description 4
- 230000009120 phenotypic response Effects 0.000 claims abstract 16
- 210000004027 cell Anatomy 0.000 claims description 371
- 108090000315 Protein Kinase C Proteins 0.000 claims description 127
- 102000003923 Protein Kinase C Human genes 0.000 claims description 125
- 230000012010 growth Effects 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 48
- 238000012360 testing method Methods 0.000 claims description 29
- 230000004044 response Effects 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 210000002950 fibroblast Anatomy 0.000 claims description 13
- 230000000877 morphologic effect Effects 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 108700020796 Oncogene Proteins 0.000 claims description 8
- 230000036755 cellular response Effects 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 208000005623 Carcinogenesis Diseases 0.000 claims description 5
- 230000036952 cancer formation Effects 0.000 claims description 5
- 231100000504 carcinogenesis Toxicity 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims description 4
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 238000007747 plating Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000000763 evoking effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 210000001768 subcellular fraction Anatomy 0.000 claims 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 46
- 239000002299 complementary DNA Substances 0.000 description 38
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000010261 cell growth Effects 0.000 description 16
- 229960001603 tamoxifen Drugs 0.000 description 15
- 230000027455 binding Effects 0.000 description 12
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 239000002644 phorbol ester Substances 0.000 description 12
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 12
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 11
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 11
- 239000000284 extract Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 8
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 8
- 230000035578 autophosphorylation Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 239000000717 tumor promoter Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102100029974 GTPase HRas Human genes 0.000 description 4
- 101710091881 GTPase HRas Proteins 0.000 description 4
- 241000713869 Moloney murine leukemia virus Species 0.000 description 4
- 101000669508 Mus musculus Metalloproteinase inhibitor 1 Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000011539 homogenization buffer Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004264 monolayer culture Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000012261 overproduction Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102100030013 Endoribonuclease Human genes 0.000 description 3
- 101710199605 Endoribonuclease Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108091005981 phosphorylated proteins Proteins 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- VXDQXODPWYRILN-UHFFFAOYSA-N 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-1h-tetrazol-1-ium;chloride;hydrate Chemical compound O.[Cl-].C1=CC([N+](=O)[O-])=CC=C1N1N(C=2C=CC(I)=CC=2)[NH+]=C(C=2C=CC=CC=2)N1 VXDQXODPWYRILN-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101710154356 Hypoxanthine/guanine phosphoribosyltransferase Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000002802 antimicrobial activity assay Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000027411 intracellular receptors Human genes 0.000 description 2
- 108091008582 intracellular receptors Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100071185 Aeromonas hydrophila subsp. hydrophila (strain ATCC 7966 / DSM 30187 / BCRC 13018 / CCUG 14551 / JCM 1027 / KCTC 2358 / NCIMB 9240 / NCTC 8049) ahh1 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101001051783 Caenorhabditis elegans Protein kinase C-like 2 Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100510329 Drosophila melanogaster Pkc53E gene Proteins 0.000 description 1
- 101100181138 Drosophila melanogaster Pkc98E gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000971468 Homo sapiens Protein kinase C zeta type Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 108700043304 PKC-3 Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100021538 Protein kinase C zeta type Human genes 0.000 description 1
- 102000012515 Protein kinase domains Human genes 0.000 description 1
- 108050002122 Protein kinase domains Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 101000717877 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-A Proteins 0.000 description 1
- 101000717881 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-B Proteins 0.000 description 1
- 101100296591 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pck2 gene Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- RHJPBGWFGOAEID-UHFFFAOYSA-N aplysiatoxin Natural products O1C2(OC(O)(CC(=O)OC(CC(=O)O3)C(C)O)C(C)CC2(C)C)CC3C(C)C1C(C)CCC(OC)C1=CC(O)=CC=C1Br RHJPBGWFGOAEID-UHFFFAOYSA-N 0.000 description 1
- 108010046507 arginyl-arginyl-lysyl-alanyl-seryl-glycyl-prolyl-prolyl-valine Proteins 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- RHJPBGWFGOAEID-BEDNPZBZSA-N chembl1256416 Chemical compound C1([C@H](CC[C@H](C)[C@@H]2[C@H]([C@@H]3C[C@@]4(O[C@@](O)(CC(=O)O[C@H](CC(=O)O3)[C@@H](C)O)[C@H](C)CC4(C)C)O2)C)OC)=CC(O)=CC=C1Br RHJPBGWFGOAEID-BEDNPZBZSA-N 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 1
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940123638 p21 inhibitor Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 108010012347 phorbol ester receptor Proteins 0.000 description 1
- 101150037186 pkc-1 gene Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- PEYTUVXFLCCGCC-YGHSORLUSA-N teleocidin b Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC([C@@](CC[C@]3(C)C=C)(C)C(C)C)=C3C3=C2C1=CN3 PEYTUVXFLCCGCC-YGHSORLUSA-N 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/154,206 US4980281A (en) | 1988-02-10 | 1988-02-10 | Method of screening for protein inhibitors and activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL89227A0 IL89227A0 (en) | 1989-09-10 |
| IL89227A true IL89227A (en) | 1995-05-26 |
Family
ID=22550430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL8922789A IL89227A (en) | 1988-02-10 | 1989-02-09 | Method of screening of protein inhibitors and activators |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4980281A (de) |
| EP (1) | EP0403506B1 (de) |
| JP (1) | JPH03503598A (de) |
| AT (1) | ATE140267T1 (de) |
| AU (1) | AU612948B2 (de) |
| BG (1) | BG60325B2 (de) |
| CA (1) | CA1334927C (de) |
| DE (1) | DE68926816T2 (de) |
| DK (2) | DK189590A (de) |
| ES (1) | ES2010131A6 (de) |
| FI (1) | FI102618B (de) |
| HU (1) | HU208555B (de) |
| IE (1) | IE77332B1 (de) |
| IL (1) | IL89227A (de) |
| MX (1) | MX165993B (de) |
| NO (2) | NO313103B1 (de) |
| RO (1) | RO118452B1 (de) |
| WO (1) | WO1989007654A1 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266464A (en) * | 1988-02-10 | 1993-11-30 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
| US5688655A (en) * | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
| US5322801A (en) * | 1990-04-19 | 1994-06-21 | The General Hospital Corporation | Protein partner screening assays and uses thereof |
| WO1991016429A1 (en) * | 1990-04-19 | 1991-10-31 | The General Hospital Corporation | Protein partner screening assays and uses thereof |
| US6080540A (en) * | 1990-04-20 | 2000-06-27 | Cold Spring Harbor Laboratory | Cloning of mammalian genes in microbial organisms and methods for pharmacological screening |
| FI931268A7 (fi) * | 1990-09-24 | 1993-04-21 | Massachusetts Gen Hospital | Seulontamenetelmiä |
| US5707810A (en) * | 1991-03-11 | 1998-01-13 | Creative Biomolecules, Inc. | Method of diagnosing renal tissue damage or disease |
| US5650276A (en) * | 1991-03-11 | 1997-07-22 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
| ATE469228T1 (de) * | 1991-04-19 | 2010-06-15 | Univ Washington | Dns, die für phosphodiesterasen von säugetieren kodiert |
| US5747341A (en) * | 1991-06-24 | 1998-05-05 | Pacific Biomedical Research, Inc. | Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture |
| ATE215605T1 (de) * | 1991-06-24 | 2002-04-15 | Pacific Biomedical Res Inc | In langzeitkultur gehaltene hormon-absondernde pankreatische zellen |
| US5821121A (en) * | 1991-06-24 | 1998-10-13 | Pacific Biomedical Research, Inc. | Hormone-secreting cells maintained in long-term culture |
| WO1993002209A1 (en) * | 1991-07-22 | 1993-02-04 | The Regents Of The University Of California | Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex |
| AU696364B2 (en) * | 1991-08-30 | 1998-09-10 | Creative Biomolecules, Inc. | Morphogenic protein screening method II |
| ATE197611T1 (de) * | 1991-08-30 | 2000-12-15 | Creative Biomolecules Inc | Screeningverfahren von morphogenischen proteinen |
| GB9216654D0 (en) * | 1992-08-05 | 1992-09-16 | Imp Cancer Res Tech | Transformed cells and assays using them |
| US6048850A (en) * | 1992-09-22 | 2000-04-11 | Young; Donald A. | Method of inhibiting prostaglandin synthesis in a human host |
| US5837479A (en) * | 1992-09-22 | 1998-11-17 | Young; Donald A. | Screening assays for inhibitors of mammalian prostaglandin H synthase-2 |
| DE4306547C2 (de) * | 1993-03-03 | 1996-07-11 | Gsf Forschungszentrum Umwelt | In-vitro-Test zur Detektion von Proteinkinase C Inhibitoren |
| AU677834B2 (en) * | 1993-04-07 | 1997-05-08 | Cancer Research Ventures Limited | Methods for screening of substances for therapeutic activityand yeast for use therein |
| US5776685A (en) * | 1993-07-19 | 1998-07-07 | Joslin Diabetes Center | Protein kinase C assay |
| JPH09510104A (ja) * | 1994-03-10 | 1997-10-14 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 形質転換の進行の誘導性阻害剤を同定する方法 |
| EP0773952B1 (de) * | 1994-07-20 | 2003-11-12 | The General Hospital Corporation | Interaktions-fullensysteme zum nachweis von protein-interaktionen |
| US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| US5597697A (en) * | 1994-09-30 | 1997-01-28 | Diamond; Paul | Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases |
| KR100402836B1 (ko) * | 1995-05-11 | 2004-02-19 | 주식회사 엘지생명과학 | 단백질간의상호작용을조절하는물질의새로운탐색시스템 |
| US6365344B1 (en) * | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| US6153380A (en) | 1996-01-23 | 2000-11-28 | Rigel Pharmaceuticals, Inc. | Methods for screening for transdominant intracellular effector peptides and RNA molecules |
| US5928888A (en) * | 1996-09-26 | 1999-07-27 | Aurora Biosciences Corporation | Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities |
| AU724107B2 (en) * | 1997-01-31 | 2000-09-14 | Fred Hutchinson Cancer Research Center | Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E |
| WO1999017798A1 (en) | 1997-10-02 | 1999-04-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| JP2001507581A (ja) | 1997-11-07 | 2001-06-12 | アイコニックス・ファーマシューティカルズ・インコーポレーテッド | 代用遺伝学的標的解析法 |
| JP2001522598A (ja) | 1997-11-10 | 2001-11-20 | ザ ジュネラル ホスピタル コーポレーション | タンパク質相互作用を記録するための検出システムおよび機能的関係 |
| US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| US6518035B1 (en) | 1998-06-02 | 2003-02-11 | Rosetta Inpharmatics, Inc. | Targeted methods of drug screening using co-culture methods |
| US6720139B1 (en) | 1999-01-27 | 2004-04-13 | Elitra Pharmaceuticals, Inc. | Genes identified as required for proliferation in Escherichia coli |
| US6589738B1 (en) | 1999-11-09 | 2003-07-08 | Elitra Pharmaceuticals, Inc. | Genes essential for microbial proliferation and antisense thereto |
| DE60143192D1 (de) | 2000-02-08 | 2010-11-18 | Sangamo Biosciences Inc | Zellen zur entdeckung von medikamenten |
| AU2001289284A1 (en) * | 2000-04-04 | 2001-10-15 | Enanta Pharmaceuticals, Inc. | Methods for identifying peptide aptamers capable of altering a cell phenotype |
| CA2408743A1 (en) * | 2000-05-25 | 2001-11-29 | Curagen Corporation | Method of detecting inflammatory lung disorders |
| US20030124524A1 (en) * | 2000-06-23 | 2003-07-03 | Kenneth Kornman | Screening assays for identifying modulators of the inflammatory or immune response |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| US20030170694A1 (en) * | 2001-12-21 | 2003-09-11 | Daniel Wall | Stabilized nucleic acids in gene and drug discovery and methods of use |
| US20040126837A1 (en) * | 2002-05-23 | 2004-07-01 | Matthew Baker | Pseudo-tissues and uses thereof |
| AU2002325299A1 (en) | 2002-07-04 | 2004-02-16 | Nalan Utku | Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof |
| EP1534856A2 (de) * | 2002-09-02 | 2005-06-01 | EVOTEC Neurosciences GmbH | Diagnostische und therapeutische verwendung von thbp im kontext neurodegenerativer erkrankungen |
| AU2003301348A1 (en) * | 2002-10-18 | 2004-05-04 | Wyeth | Compositions and methods for diagnosing and treating autoimmune disease |
| DE602004015064D1 (de) | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
| US20050266409A1 (en) * | 2003-02-04 | 2005-12-01 | Wyeth | Compositions and methods for diagnosing, preventing, and treating cancers |
| WO2004076639A2 (en) * | 2003-02-26 | 2004-09-10 | Wyeth | Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
| KR20050106483A (ko) * | 2003-03-04 | 2005-11-09 | 와이어쓰 | 천식 또는 그 밖의 알러지성 또는 염증성 질환을 진단 및치료하기 위한 조성물 및 방법 |
| WO2004094647A2 (en) * | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| WO2005001092A2 (en) * | 2003-05-20 | 2005-01-06 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| US8071652B2 (en) * | 2003-08-21 | 2011-12-06 | The Board Of Regents Of The University Of Texas System | Method of treating irritable bowel syndrome |
| US20050164167A1 (en) * | 2004-01-28 | 2005-07-28 | Buscher Benjamin A. | Method of discovery and development of broad-spectrum antiviral drugs |
| AU2005247943A1 (en) | 2004-05-23 | 2005-12-08 | Gerard M. Housey | Theramutein modulators |
| US8431110B2 (en) | 2005-05-23 | 2013-04-30 | Hmi Medical Innovations, Llc. | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators |
| CA2631182C (en) * | 2005-11-23 | 2019-08-06 | Hmi, Inc. | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators |
| EP1878744A1 (de) * | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren |
| AU2007353317B2 (en) * | 2006-11-15 | 2012-09-06 | Eli Lilly And Company | Methods and compositions for treating influenza |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4480038A (en) * | 1982-04-30 | 1984-10-30 | E. I. Dupont De Nemours And Company | Density separation of protein overproducing bacteria |
| US4532204A (en) * | 1982-07-19 | 1985-07-30 | Massachusetts Institute Of Technology | Mutation assays involving blood cells that metabolize toxic substances |
| US5266464A (en) * | 1988-02-10 | 1993-11-30 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
-
1988
- 1988-02-10 US US07/154,206 patent/US4980281A/en not_active Expired - Lifetime
-
1989
- 1989-02-08 ES ES8900455A patent/ES2010131A6/es not_active Expired
- 1989-02-08 IE IE39889A patent/IE77332B1/en not_active IP Right Cessation
- 1989-02-09 EP EP89902686A patent/EP0403506B1/de not_active Revoked
- 1989-02-09 RO RO145730A patent/RO118452B1/ro unknown
- 1989-02-09 WO PCT/US1989/000462 patent/WO1989007654A1/en not_active Ceased
- 1989-02-09 HU HU891433A patent/HU208555B/hu not_active IP Right Cessation
- 1989-02-09 DE DE68926816T patent/DE68926816T2/de not_active Expired - Fee Related
- 1989-02-09 AU AU31840/89A patent/AU612948B2/en not_active Ceased
- 1989-02-09 AT AT89902686T patent/ATE140267T1/de not_active IP Right Cessation
- 1989-02-09 CA CA000590540A patent/CA1334927C/en not_active Expired - Fee Related
- 1989-02-09 IL IL8922789A patent/IL89227A/en not_active IP Right Cessation
- 1989-02-09 JP JP1502499A patent/JPH03503598A/ja active Pending
- 1989-02-10 MX MX014890A patent/MX165993B/es unknown
-
1990
- 1990-08-08 NO NO19903494A patent/NO313103B1/no not_active IP Right Cessation
- 1990-08-08 FI FI903918A patent/FI102618B/fi not_active IP Right Cessation
- 1990-08-09 DK DK189590A patent/DK189590A/da not_active Application Discontinuation
- 1990-08-10 BG BG092673A patent/BG60325B2/bg unknown
-
2001
- 2001-05-08 DK DK200100720A patent/DK200100720A/da not_active Application Discontinuation
-
2002
- 2002-03-07 NO NO20021142A patent/NO20021142D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO903494D0 (no) | 1990-08-08 |
| BG60325B2 (bg) | 1994-05-27 |
| FI903918A0 (fi) | 1990-08-08 |
| NO20021142D0 (no) | 2002-03-07 |
| DK189590D0 (da) | 1990-08-09 |
| JPH03503598A (ja) | 1991-08-15 |
| ES2010131A6 (es) | 1989-10-16 |
| MX165993B (es) | 1992-12-15 |
| FI102618B1 (fi) | 1999-01-15 |
| IE890398L (en) | 1989-08-10 |
| RO118452B1 (ro) | 2003-05-30 |
| EP0403506A4 (en) | 1991-07-24 |
| NO903494L (no) | 1990-10-01 |
| IE77332B1 (en) | 1997-12-02 |
| DE68926816T2 (de) | 1997-01-09 |
| NO20021142L (no) | 1990-10-01 |
| CA1334927C (en) | 1995-03-28 |
| DK200100720A (da) | 2001-05-08 |
| WO1989007654A1 (en) | 1989-08-24 |
| AU3184089A (en) | 1989-09-06 |
| DE68926816D1 (de) | 1996-08-14 |
| ATE140267T1 (de) | 1996-07-15 |
| IL89227A0 (en) | 1989-09-10 |
| AU612948B2 (en) | 1991-07-18 |
| HU208555B (en) | 1993-11-29 |
| HUT55447A (en) | 1991-05-28 |
| FI102618B (fi) | 1999-01-15 |
| EP0403506A1 (de) | 1990-12-27 |
| NO313103B1 (no) | 2002-08-12 |
| DK189590A (da) | 1990-10-02 |
| US4980281A (en) | 1990-12-25 |
| EP0403506B1 (de) | 1996-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4980281A (en) | Method of screening for protein inhibitors and activators | |
| US5688655A (en) | Method of screening for protein inhibitors and activators | |
| US5266464A (en) | Method of screening for protein inhibitors and activators | |
| Housey et al. | Overproduction of protein kinase C causesdisordered growth control in rat fibroblasts | |
| Sgouras et al. | ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets‐associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. | |
| Campbell et al. | Identification of regions in polyomavirus middle T and small t antigens important for association with protein phosphatase 2A | |
| Li et al. | Effect of mutations at serines 1280–1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor | |
| Heidecker et al. | Role of raf and myc oncogenes in signal transduction | |
| Druker et al. | A completely transformation-defective point mutant of polyomavirus middle T antigen which retains full associated phosphatidylinositol kinase activity | |
| Housey et al. | Structural and functional studies of protein kinase C | |
| CA2546811A1 (en) | Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a src family kinase | |
| Kubota et al. | Relocalization of Drosophila dorsal protein can be induced by a rise in cytoplasmic calcium concentration and the expression of constitutively active but not wild-type Toll receptors | |
| Shu et al. | Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain | |
| Topol et al. | Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf | |
| Hayne | Regulation of the Raf-1/MEK/ERK signaling module in mitosis | |
| Vasudevan et al. | The elevation of cellular phosphatidic acid levels caused by polyomavirus transformation can be disassociated from the activation of phospholipase D | |
| US20050065081A1 (en) | Tyrosine kinase inhibitors | |
| David | Proximal events in integrin-mediated signaling | |
| Ignatoski | Biochemical and biological analysis of the autophosphorylation requirement for kinase activity and transforming ability of proteins encoded by host-range V-SRC alleles | |
| Campbell | Functional analysis of conserved sequence motifs in polyomavirus tumor antigens required for interactions with cellular proteins | |
| Lin | Dissecting p56 (lck) function in developing thymocytes | |
| Chen | Regulation ofras signaling by Gs-alpha | |
| Silverstein | Characterization of an SV40 transformation revertant cell line | |
| Weiner | The role of simian virus 40 large tumor antigen in initiation of DNA replication | |
| PH | SH2 SH2 SH3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |